Michael Martin
President & CEO of Plexium
San Diego, California
Overview
Work Experience
President & CEO
2024 - Current
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.
Raised $165,000,000.00 from CRV, RA Capital Management, Pappas Capital, DCVC Bio, SoftBank Vision Fund, Pivotal bioVenture Partners, M Ventures, Surveyor Capital, Lux Capital and Neotribe Ventures.
Head of Center for External Innovation
2022 - 2024
Head of Center for External Innovation
2022 - 2024
Takeda Ventures, Inc.
2015 - 2024
Global Licensing & Business Development
2012 - 2015
Head, Intellikine Integration
2012 - 2012
.
2008 - 2012
.
2005 - 2008
TargeGen, Inc., a vascular biology-focused biopharmaceutical company, discovers and develops small molecule kinase inhibitors that target.
Raised $113,718,379.00 from CTI Life Sciences Fund, Hambrecht & Quist Capital Management, Chicago Growth Partners, Innovis Investments, Forward Ventures, CDP Capital Technology Ventures, VantagePoint Capital Partners, BB Biotech Ventures, Pappas Ventures and Enterprise Partners.
.
2000 - 2005
Arena Pharmaceuticals is focused on delivering solutions for cardiovascular, central nervous system, inflammatory and metabolic diseases.
Raised $1,059,760,000.00 from Farallon Capital Management, Deerfield Capital Management, Deerfield Capital Management and Deerfield.